Current Concepts in the Treatment of MASH
CME
Monday, July 6, 2026 | 5:30 pm - 6:00 pm ET
Supported by an independent educational grant from Madrigal Pharmaceuticals.
overview
In this engaging webinar, Dr Stephen Flamm and Dr Tejas Joshi will take a deep dive into treatments for metabolic dysfunction-associated steatohepatitis (MASH). Faculty will provide a comprehensive review of the 2 currently approved MASH-directed therapies, resmetirom and semaglutide, review evidence-based selection of treatments, sequencing of therapies, and how to monitor patients on therapy for safety and response. Learners will come away with a better understanding of how to individualize therapy for their patients as part of patient-centered MASH care.
faculty
target audience
This educational activity is intended for an audience of hepatologists/gastroenterologist, diabetologists/endocrinologists, nurse practitioners/physician assistants, and nurses in the United States.
goal statement
The goal of this activity is for learners to be better able to design treatment strategies for patients with F2/F3 (MASH).
learning objectives
accreditation statement
In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.